Piper Sandler analyst Alexander Potter downgrades Shift Technologies (NASDAQ:SFT) from Overweight to Neutral.
Moleculin Provides Update On Second Multiple Ascending Dose (MAD) Cohort In Phase 1a Clinical Trial Of WP1122 In UK; Shares Move Lower
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors
